Is Rhodiola Cognitive Function Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Rhodiola Cognitive Function Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Background: Rhodiola rosea (RR) is marketed as an adaptogen; however, evidence for acute/short-term effects-and especially dose-response effects-in trained adults across performance and cognition is limited. [Koozehchian MS (2025); evidence level 2] - Results: Versus CON, LDRR increased BP 1RM (+5.59 kg; p = 0.003), set-3 repetitions (+4.30; p p p = 0.026). [Koozehchian MS (2025); evidence level 2] - HDRR increased set-3 repetitions (+2.78; p = 0.005) and peak power (+34.2 W; p = 0.026), with a trend for set-3 volume ( p = 0.086). [Koozehchian MS (2025); evidence level 2] - Objective: Test whether RR improves resistance performance (strength, power) and executive function in resistance-trained adults using a randomized crossover with placebo and a capsule-free baseline. [Koozehchian MS (2025); evidence level 2] - Some nutrients and phytonutrients also improved mood and contentedness and reduced anxiety and the need for caregiving. [Lewis JE (2021); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.